Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease

Wen-Yu Hsu, Hsien-Yuan Lane, Chieh-Hsin Lin, Wen-Yu Hsu, Hsien-Yuan Lane, Chieh-Hsin Lin

Abstract

Background/aims: Cognitive impairment, which frequently occurs in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease, has a significant impact on the daily lives of both patients and their family. Furthermore, since the medications used for cognitive enhancement have limited efficacy, the issue of cognitive enhancement still remains a clinically unsolved challenge.

Sampling and methods: We reviewed the clinical studies (published between 2007 and 2017) that focused on the efficacy of medications used for enhancing cognition in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease.

Results: Acetylcholinesterase inhibitors and memantine are the standard treatments for Alzheimer's disease and Parkinson's disease. Some studies have reported selective cognitive improvement in patients with schizophrenia following galantamine treatment. Newer antipsychotics, including paliperidone, lurasidone, aripiprazole, ziprasidone, and BL-1020, have also been reported to exert cognitive benefits in patients with schizophrenia. Dopaminergic medications were found to improve language function in patients with Parkinson's disease. However, no beneficial effects on cognitive function were observed with dopamine agonists in patients with schizophrenia. The efficacies of nicotine and its receptor modulators in cognitive improvement remain controversial, with the majority of studies showing that varenicline significantly improved the cognitive function in schizophrenic patients. Several studies have reported that N-methyl-d-aspartate glutamate receptor (NMDAR) enhancers improved the cognitive function in patients with chronic schizophrenia. NMDAR enhancers might also have cognitive benefits in patients with Alzheimer's disease or Parkinson's disease. Raloxifene, a selective estrogen receptor modulator, has also been demonstrated to have beneficial effects on attention, processing speed, and memory in female patients with schizophrenia.

Conclusion: Clinical trials with larger sample sizes evaluating comprehensive cognitive domains are warranted to examine the efficacy of medications in cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease.

Keywords: Alzheimer’s disease; Parkinson’s disease; bipolar disorder; cognitive impairment; medication; schizophrenia.

References

    1. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry (2006) 67(Suppl 9):3–8; discussion 36–42.10.4088/JCP.1006e12
    1. Wisdom NM, Mignogna J, Collins RL. Variability in Wechsler Adult Intelligence Scale-IV subtest performance across age. Arch Clin Neuropsychol (2012) 27(4):389–97.10.1093/arclin/acs041
    1. Humes LE, Floyd SS. Measures of working memory, sequence learning, and speech recognition in the elderly. J Speech Lang Hear Res (2005) 48(1):224–35.10.1044/1092-4388(2005/016)
    1. Heaton R, Paulsen JS, McAdams LA, Kuck J, Zisook S, Braff D, et al. Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry (1994) 51(6):469–76.10.1001/archpsyc.1994.03950060033003
    1. Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res (1997) 28(2–3):111–25.10.1016/S0920-9964(97)85354-6
    1. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology (1998) 12(3):426–45.10.1037/0894-4105.12.3.426
    1. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 31(9):2033–46.10.1038/sj.npp.1301072
    1. Savla GN, Vella L, Armstrong CC, Penn DL, Twamley EW. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull (2013) 39(5):979–92.10.1093/schbul/sbs080
    1. Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand (2013) 128(3):149–62.10.1111/acps.12133
    1. Samame C, Martino DJ, Strejilevich SA. Social cognition in euthymic bipolar disorder: systematic review and meta-analytic approach. Acta Psychiatr Scand (2012) 125(4):266–80.10.1111/j.1600-0447.2011.01808.x
    1. Daban C, Martinez-Aran A, Torrent C, Tabares-Seisdedos R, Balanza-Martinez V, Salazar-Fraile J, et al. Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother Psychosom (2006) 75(2):72–84.10.1159/000090891
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 256(3):183–94.10.1111/j.1365-2796.2004.01388.x
    1. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA (2002) 288(12):1475–83.10.1001/jama.288.12.1475
    1. Lesh TA, Westphal AJ, Niendam TA, Yoon JH, Minzenberg MJ, Ragland JD, et al. Proactive and reactive cognitive control and dorsolateral prefrontal cortex dysfunction in first episode schizophrenia. Neuroimage Clin (2013) 2:590–9.10.1016/j.nicl.2013.04.010
    1. Zandbelt BB, van Buuren M, Kahn RS, Vink M. Reduced proactive inhibition in schizophrenia is related to corticostriatal dysfunction and poor working memory. Biol Psychiatry (2011) 70(12):1151–8.10.1016/j.biopsych.2011.07.028
    1. Eich TS, Nee DE, Insel C, Malapani C, Smith EE. Neural correlates of impaired cognitive control over working memory in schizophrenia. Biol Psychiatry (2014) 76(2):146–53.10.1016/j.biopsych.2013.09.032
    1. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci (2012) 16(1):27–34.10.1016/j.tics.2011.11.015
    1. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC. Inflammatory mediators of cognitive impairment in bipolar disorder. J Psychiatr Res (2014) 56:18–27.10.1016/j.jpsychires.2014.04.017
    1. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 7(2):129–35.10.1016/S1474-4422(08)70001-2
    1. Selkoe DJ. Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci (2000) 924:17–25.10.1111/j.1749-6632.2000.tb05554.x
    1. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 10(1):24–35.10.1097/00019442-200201000-00004
    1. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL. The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing Res Rev (2013) 12(3):757–63.10.1016/j.arr.2013.03.002
    1. Hu NW, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer’s disease: update on recent advances. Pharmacol Biochem Behav (2012) 100(4):855–62.10.1016/j.pbb.2011.04.013
    1. Caballol N, Marti MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord (2007) 22(Suppl 17):S358–66.10.1002/mds.21677
    1. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol (2012) 11(8):697–707.10.1016/S1474-4422(12)70152-7
    1. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ (1999) 318(7184):633–8.10.1136/bmj.318.7184.633
    1. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ (2000) 321(7274):1445–9.10.1136/bmj.321.7274.1445
    1. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia (1996) 7(6):293–303.
    1. U.S. Food and Drug Administration Aricept ODT (Donepezil HCI) Orally Disintegrating Tablets approval letter. (2004). Available from:
    1. U.S. Food and Drug Administration Razadyne (Galantamine Hydrobromide) ER (Formerly Reminyl) approval letter. (2004). Available from:
    1. U.S. Food and Drug Administration Exelon Patch (rivastigmine transdermal system) approval letter. (2007). Available from:
    1. Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol (2007) 22(2):63–8.10.1097/YIC.0b013e3280117feb
    1. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2008) 165(1):82–9.10.1176/appi.ajp.2007.07050724
    1. Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res (2008) 102(1–3):88–95.10.1016/j.schres.2007.12.491
    1. Sacco KA, Creeden C, Reutenauer EL, George TP. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. Schizophr Res (2008) 103(1–3):326–7.10.1016/j.schres.2008.05.004
    1. Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res (2011) 125(2–3):267–77.10.1016/j.schres.2010.08.021
    1. Akhondzadeh S, Gerami M, Noroozian M, Karamghadiri N, Ghoreishi A, Abbasi SH, et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32(8):1810–5.10.1016/j.pnpbp.2008.08.001
    1. Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol (2007) 21(4):421–7.10.1177/0269881106070996
    1. Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol (2007) 30(1):3–12.10.1097/01.WNF.0000240940.67241.F6
    1. Chung YC, Lee CR, Park TW, Yang KH, Kim KW. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry (2009) 10(2):156–62.10.1080/15622970701432551
    1. Chouinard S, Stip E, Poulin J, Melun JP, Godbout R, Guillem F, et al. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin (2007) 23(3):575–83.10.1185/030079906X167372
    1. Morozova MA, Beniashvili AG, Rupchev GE, Lepilkina TA, Starostin DS, Brusov OS. [Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits]. Zh Nevrol Psikhiatr Im S S Korsakova (2008) 108(11):28–35.
    1. Iosifescu DV, Moore CM, Deckersbach T, Tilley CA, Ostacher MJ, Sachs GS, et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS Neurosci Ther (2009) 15(4):309–19.10.1111/j.1755-5949.2009.00090.x
    1. Gildengers AG, Butters MA, Chisholm D, Reynolds CF, Mulsant BH. A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry (2008) 23(7):693–8.10.1002/gps.1962
    1. Ghaemi SN, Gilmer WS, Dunn RT, Hanlon RE, Kemp DE, Bauer AD, et al. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol (2009) 29(3):291–5.10.1097/JCP.0b013e3181a497d7
    1. Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol (2008) 38(9):937–45.10.1007/s11055-008-9077-3
    1. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry (2009) 80(1):18–23.10.1136/jnnp.2008.144048
    1. Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord (2015) 30(7):912–8.10.1002/mds.26236
    1. Li Z, Yu Z, Zhang J, Wang J, Sun C, Wang P, et al. Impact of rivastigmine on cognitive dysfunction and falling in Parkinson’s disease patients. Eur Neurol (2015) 74(1–2):86–91.10.1159/000438824
    1. U.S. Food and Drug Administration Namenda (Memantine HCI) approval letter. (2003). Available from:
    1. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology (2007) 53(6):699–723.10.1016/j.neuropharm.2007.07.013
    1. Krivoy A, Weizman A, Laor L, Hellinger N, Zemishlany Z, Fischel T. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: a preliminary study. Eur Neuropsychopharmacol (2008) 18(2):117–21.10.1016/j.euroneuro.2007.07.008
    1. Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology (2009) 34(5):1322–9.10.1038/npp.2008.200
    1. Lee JG, Lee SW, Lee BJ, Park SW, Kim GM, Kim YH. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig (2012) 9(2):166–73.10.4306/pi.2012.9.2.166
    1. de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry (2009) 70(10):1416–23.10.4088/JCP.08m04935gry
    1. Veerman SR, Schulte PF, Smith JD, de Haan L. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med (2016) 46(9):1909–21.10.1017/S0033291716000398
    1. Veerman SR, Schulte PF, Deijen JB, de Haan L. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychol Med (2017) 47(2):363–75.10.1017/S0033291716002476
    1. Mazinani R, Nejati S, Khodaei M. Effects of memantine added to risperidone on the symptoms of schizophrenia: a randomized double-blind, placebo-controlled clinical trial. Psychiatry Res (2017) 247:291–5.10.1016/j.psychres.2016.09.028
    1. Litvinenko IV, Odinak MM, Mogil’naya VI, Perstnev SV. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson’s disease complicated by dementia. Neurosci Behav Physiol (2010) 40(2):149–55.10.1007/s11055-009-9244-1
    1. Suzuki H, Gen K. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Hum Psychopharmacol (2012) 27(5):470–5.10.1002/hup.2249
    1. Takekita Y, Koshikawa Y, Fabbri C, Sakai S, Sunada N, Onohara A, et al. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry (2016) 16:172.10.1186/s12888-016-0883-9
    1. Suzuki H, Gen K, Inoue Y, Hibino H, Mikami A, Matsumoto H, et al. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Int J Psychiatry Clin Pract (2014) 18(1):58–62.10.3109/13651501.2013.845218
    1. Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol (2012) 27(5):267–74.10.1097/YIC.0b013e328356acad
    1. Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol (2013) 23(11):1373–82.10.1016/j.euroneuro.2013.08.003
    1. Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res (2015) 166(1–3):334–8.10.1016/j.schres.2015.06.008
    1. Muscatello MR, Pandolfo G, Mico U, Lamberti Castronuovo E, Abenavoli E, Scimeca G, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol (2014) 34(1):129–33.10.1097/JCP.0000000000000042
    1. Harvey PD, Sacchetti E, Galluzzo A, Romeo F, Gorini B, Bilder RM, et al. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr Res (2008) 105(1–3):138–43.10.1016/j.schres.2007.11.014
    1. Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, et al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: results from the ESCAPE study. CNS Drugs (2012) 26(11):975–82.10.1007/s40263-012-0003-4
    1. Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. Bl-1020, a new gamma-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry (2012) 73(9):e1168–74.10.4088/JCP.12m07642
    1. Cole DM, Oei NY, Soeter RP, Both S, van Gerven JM, Rombouts SA, et al. Dopamine-dependent architecture of cortico-subcortical network connectivity. Cereb Cortex (2013) 23(7):1509–16.10.1093/cercor/bhs136
    1. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry (1980) 137:383–6.
    1. Pezze MA, Dalley JW, Robbins TW. Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology (2007) 32(2):273–83.10.1038/sj.npp.1301073
    1. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science (1991) 251(4996):947–50.10.1126/science.1825731
    1. Murray AM, Ryoo HL, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A (1994) 91(23):11271–5.10.1073/pnas.91.23.11271
    1. Kelleher JP, Centorrino F, Huxley NA, Bates JA, Drake JK, Egli S, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol (2012) 22(6):415–8.10.1016/j.euroneuro.2011.10.002
    1. Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol (2016) 30(5):428–35.10.1177/0269881116636120
    1. Burdick KE, Braga RJ, Nnadi CU, Shaya Y, Stearns WH, Malhotra AK. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry (2012) 73(1):103–12.10.4088/JCP.11m07299
    1. Brusa L, Pavino V, Massimetti MC, Bove R, Iani C, Stanzione P. The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson’s disease patients. Funct Neurol (2013) 28(1):13–7.
    1. Murakami H, Momma Y, Nohara T, Mori Y, Futamura A, Sugita T, et al. Improvement in language function correlates with gait improvement in drug-naive Parkinson’s disease patients taking dopaminergic medication. J Parkinsons Dis (2016) 6(1):209–17.10.3233/JPD-150702
    1. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2008) 33(3):480–90.10.1038/sj.npp.1301423
    1. Boggs DL, Ranganathan M, Sewell RA, Madonick S, D’Souza DC. Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia. Schizophr Res (2013) 150(1):323–4.10.1016/j.schres.2013.07.045
    1. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res (2009) 110(1–3):149–55.10.1016/j.schres.2009.02.001
    1. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2012) 37(3):660–8.10.1038/npp.2011.238
    1. Velligan D, Brenner R, Sicuro F, Walling D, Riesenberg R, Sfera A, et al. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr Res (2012) 134(1):59–64.10.1016/j.schres.2011.10.004
    1. Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology (2015) 40(13):3053–60.10.1038/npp.2015.176
    1. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology (2013) 38(6):968–75.10.1038/npp.2012.259
    1. Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr Bull (2016) 42(2):335–43.10.1093/schbul/sbv072
    1. Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, et al. A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology (2014) 39(7):1568–77.10.1038/npp.2014.17
    1. Frolich L, Ashwood T, Nilsson J, Eckerwall G, Sirocco I. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer’s disease: a phase IIb dose-finding study. J Alzheimers Dis (2011) 24(2):363–74.10.3233/JAD-2011-101554
    1. Holmes AD, Copland DA, Silburn PA, Chenery HJ. Acute nicotine enhances strategy-based semantic processing in Parkinson’s disease. Int J Neuropsychopharmacol (2011) 14(7):877–85.10.1017/S1461145710001665
    1. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 164(10):1593–602.10.1176/appi.ajp.2007.06081358
    1. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res (2008) 106(2–3):320–7.10.1016/j.schres.2008.08.012
    1. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 121(1–3):125–30.10.1016/j.schres.2010.05.012
    1. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry (2013) 70(12):1267–75.10.1001/jamapsychiatry.2013.2159
    1. Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, et al. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl) (2009) 202(1–3):411–7.10.1007/s00213-008-1278-5
    1. Shen Y, Hu WW, Fan YY, Dai HB, Fu QL, Wei EQ, et al. Carnosine protects against NMDA-induced neurotoxicity in differentiated rat PC12 cells through carnosine-histidine-histamine pathway and H(1)/H(3) receptors. Biochem Pharmacol (2007) 73(5):709–17.10.1016/j.bcp.2006.11.007
    1. Shen Y, He P, Fan YY, Zhang JX, Yan HJ, Hu WW, et al. Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity. Free Radic Biol Med (2010) 48(5):727–35.10.1016/j.freeradbiomed.2009.12.021
    1. Chengappa KN, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ, et al. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res (2012) 142(1–3):145–52.10.1016/j.schres.2012.10.001
    1. Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry (2014) 75(9):678–85.10.1016/j.biopsych.2013.08.010
    1. Tsai CH, Huang HC, Liu BL, Li CI, Lu MK, Chen X, et al. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson’s disease with dementia. Psychiatry Clin Neurosci (2014) 68(9):692–700.10.1111/pcn.12175
    1. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A (2001) 98(7):4044–9.10.1073/pnas.051606598
    1. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A (1998) 95(8):4635–40.10.1073/pnas.95.8.4635
    1. Siren AL, Ehrenreich H. Erythropoietin – a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci (2001) 251(4):179–84.10.1007/s004060170038
    1. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry (2007) 12(2):206–20.10.1038/sj.mp.4001907
    1. Pedroso I, Bringas ML, Aguiar A, Morales L, Alvarez M, Valdes PA, et al. Use of Cuban recombinant human erythropoietin in Parkinson’s disease treatment. MEDICC Rev (2012) 14(1):11–7.
    1. Jang W, Park J, Shin KJ, Kim JS, Kim JS, Youn J, et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson’s disease. J Neurol Sci (2014) 337(1–2):47–54.10.1016/j.jns.2013.11.015
    1. Miskowiak KW, Ehrenreich H, Christensen EM, Kessing LV, Vinberg M. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry (2014) 75(12):1347–55.10.4088/JCP.13m08839
    1. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol (1994) 83(6):979–83.10.1097/00006250-199406000-00017
    1. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology (1997) 49(6):1491–7.10.1212/WNL.49.6.1491
    1. Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol (2014) 24(2):223–31.10.1016/j.euroneuro.2013.11.012
    1. Henderson VW, Ala T, Sainani KL, Bernstein AL, Stephenson BS, Rosen AC, et al. Raloxifene for women with Alzheimer disease: a randomized controlled pilot trial. Neurology (2015) 85(22):1937–44.10.1212/WNL.0000000000002171
    1. Rupprecht R, di Michele F, Hermann B, Strohle A, Lancel M, Romeo E, et al. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res Brain Res Rev (2001) 37(1–3):59–67.10.1016/S0165-0173(01)00123-0
    1. Strous RD, Stryjer R, Maayan R, Gal G, Viglin D, Katz E, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology (2007) 32(2):96–105.10.1016/j.psyneuen.2006.11.002

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner